Clinical-stage biopharma developing molecules targeting cancer resistance.
| Date | Round | Amount |
|---|---|---|
| Dec 2023 | Series A French biopharma NETRIS Pharma raised a EUR7.5M Series A extension (round now EUR24.4M) with EIC Fund to advance its cancer therapeutics. | $8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.